Teva Debuts US Rituximab At A 10% Discount
Truxima Biosimilar Rival To Rituxan Is Licensed From Celltrion
Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.
Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.